ALZHEIMER'S DISEASE TREATMENT WITH MULTIPLE THERAPEUTIC AGENTS DELIVERED TO THE OLFACTORY REGION THROUGH A SPECIAL DELIVERY CATHETER AND IONTOPHORESIS

• US 20140012182A1
• Filed: 07/18/2013
• Published: 01/09/2014
• Est. Priority Date: 05/16/2012
• Status: Abandoned Application

• Current Assignee: Wedge Therapeutics, LLC
• Original Assignee: Wedge Therapeutics, LLC
• Inventors: Shantha, Totada R.
• Application Number:
  US13/945,087
• Publication Number:
  US 20140012182A1
• Time in Patent Office: Days
• US Class Current: 604/21
• CPC Class Codes: A61M 31/00 Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008
• CPC Class Codes: A61N 1/0546 Nasal electrodes
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
• CPC Class Codes: A61N 1/303 Constructional details electrodes for external use A61N1/0428
• CPC Class Codes: A61N 1/306 Arrangements where at least part of the apparatus is introduced into the body
• CPC Class Codes: A61N 1/325 for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body electrodes for external use A61N1/0428
• CPC Class Codes: A61N 1/327 for enhancing the absorption properties of tissue, e.g. by electroporation
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer'"'"'s disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE.

Claims

1-13. -13. (canceled)

14. An apparatus for electrically stimulating nerves in a region of a nasal cavity, the apparatus comprising

an elongate shaft having a proximal end and an insertion end, the insertion end adapted for placement at a trans-nasal location within the nasal cavity extending from an exterior nasal opening, along the nasal cavity adjacent to olfactory mucosa, and to an interior of a sphenoid sinus,

the insertion end comprising

a distal electrode adapted to be located within the sphenoid sinus with the insertion end located at the trans-nasal location, and

a proximal electrode adapted to be located adjacent olfactory mucosa with the insertion end located at the trans-nasal location.

15. An apparatus as recited at claim 14 comprising

an expandable surface at the insertion end adapted for placement and expansion within a sphenoid sinus with the insertion end located at the trans-nasal location,

wherein

the distal electrode is located at the expandable surface and is adapted to expand within the sphenoid sinus, and

the proximal electrode is located on a proximal side of the expandable surface to be located adjacent olfactory mucosa with the insertion end located at the trans-nasal location.

16. An apparatus as recited at claim 14 wherein the expandable surface comprises a balloon and the distal electrode is one of multiple bipolar distal electrodes located at an exterior of the balloon.

17. An apparatus as recited at claim 16 wherein the bipolar distal electrodes are at the exterior and are adapted to contact an interior of the sphenoid sinus with the balloon expanded within the sphenoid sinus.

18. An apparatus as recited at claim 14 wherein the proximal electrode is one of multiple bipolar proximal electrodes located along a length of the insertion end on a proximal side of the expandable surface.

19. An apparatus as recited at claim 14 capable of delivering an electrical impulse to stimulate a nerve of the olfactory mucosa.

20. An apparatus as recited at claim 14 capable of delivering an electrical impulse to stimulate cranial nerves.

21. An apparatus as recited at claim 14 capable of delivering an electrical impulse to stimulate hypophyseal gland and hypothalmo-hypophyseal tract.

22. An apparatus as recited at claim 14 wherein, with placement of the proximal electrode or electrodes adjacent olfactory mucosa with the insertion end located as the trans-nasal location, the proximal electrodes can be activated to stimulate olfactory nerves.

23. An apparatus as recited at claim 15 comprising a second expandable surface on a proximal side of the proximal electrode, wherein the expandable surface adapted for placement within a sphenoid sinus can be expanded to secure the insertion end at the trans-nasal location.

24. An apparatus as recited at claim 15 wherein the expandable surface adapted for placement within a sphenoid sinus can be alternately expanded and retracted, and in the retracted state can be passed through the sphenoid ostium to place the expandable surface within the sphenoid sinus.

25. An apparatus as recited at claim 14 wherein the proximal end comprises:

a proximal electrode connector in electrical communication with the proximal electrode, and

a distal electrode connector in electrical communication with the distal electrode.

26. An apparatus as recited at claim 14 wherein the insertion end comprises a fluid delivery orifice and the proximal end comprises a syringe in communication with the fluid delivery orifice.

27. An apparatus as recited at claim 26 wherein the insertion end comprises a second fluid delivery device and the proximal end comprises a second syringe in communication with the fluid delivery device.

28. An apparatus as recited at claim 26 wherein the fluid delivery orifice is located to eject fluid to a contact a sphenoid sinus or olfactory mucosa, with the insertion end located at the trans-nasal location.

29. An apparatus as recited at claim 27 wherein the fluid delivery orifice is located to eject fluid to contact a sphenoid sinus and the second fluid delivery orifice is located to eject fluid to contact olfactory mucosa, with the insertion end located at the trans-nasal location.

30. An apparatus as recited at claim 14 in combination with an electric stimulator adapted to be located exterior to the exterior nasal opening with the insertion end located at the trans-nasal location, the stimulator comprising a power source, a control device, a first connector adapted to electronically engage the proximal electrode connector to deliver an electronic stimulation signal to the proximal electrode or electrodes, and a second connector adapted to electronically engage the distal electrode connector to deliver an electronic stimulation signal to the distal electrode or electrodes.

31. An apparatus as recited at claim 23 wherein the second expandable surface comprises an inflatable balloon.

32. A method of nerve stimulation, the method comprising

providing an apparatus as recited at claim 14,

inserting the insertion end into the exterior nasal opening and nasal cavity to place the insertion end at the trans-nasal location with the distal electrode at an interior of the sphenoid sinus and the proximal electrode adjacent to olfactory mucosa,

delivering a distal electrical signal to the distal electrode, and

delivering a proximal electrical signal to the proximal electrode.

33. A method as recited at claim 32 wherein the proximal electrical signal stimulates an olfactory nerve.

34. A method as recited at claim 33 wherein the distal electrical signal stimulates 5 pairs of cranial nerves, pituitary gland, and hypothalmo-hypophyseal tract.

35. A method as recited at claim 33 wherein the shaft comprises a fluid delivery lumen extending between the proximal end and insertion end, and the method comprises delivering a liquid fluid to the sphenoid sinus, olfactory mucosa, or both.

36. A method of treating Parkinson'"'"'s disease, the method comprising

providing an apparatus as recited at claim 14,

inserting the insertion end into the exterior nasal opening and nasal cavity to place the insertion end at the trans-nasal location with the distal electrode at an interior of the sphenoid sinus and the proximal electrode adjacent to olfactory mucosa,

delivering a distal electrical signal to the distal electrode, and

delivering a proximal electrical signal to the proximal electrode.